Company Profile
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the R&D of biological drugs, such as antibodies that address high unmet medical needs.
The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS diseases, as well as Lecanemab for intravenous treatment. It also is developing Lecanemab for Subcutaneous treatment, which is in registration stage.
Its portfolio also includes lecanemab, which is in phase 3 clinical trials for presymptomatic treatment, Exidavnemab, which is in phase 2 clinical trials, Lecanemab back-up, BAN2803, ND3014, and BAN2802 that are in preclinical trials, and ND-BT8825, HD-BT4801, GD-BT6822, ND-BT3814, PD-BT2238 which are in research stage.
The company has research and collaboration agreement with Eli Lilly to develop a new drug candidate combining the BrainTransporter technology with a Lilly proprietary molecule.
Formerly known as BioArctic Neuroscience AB, the company rebranded as BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.